10-K/A: Nutex Health Q4 2024: Revenue Soars, Profit Returns Amid Restatement

Nutex Health Inc. reported a significant financial turnaround in 2024 with a net income of $52.1 million, driven by a 93.8% revenue increase to $479.9 million, despite restating prior financials and identifying additional material weaknesses in internal controls.

Summary

• Nutex Health Inc. filed an Amendment No. 2 on Form 10-K/A to restate its consolidated financial statements for the year ended December 31, 2024, primarily to reclassify $16.4 million in non-cash stock-based compensation obligations from equity to liabilities.
• The restatement also included reclassifying $3.5 million in related-party accounts payable to equity, moving $2.9 million from cash to restricted short-term investments, and adjusting accrued income tax expense by $0.5 million.
• Total liabilities increased by $13.4 million (2.9%), total equity decreased by $13.4 million (6.6%), and net income decreased by approximately $0.5 million (0.5%) due to these adjustments.
• Net income attributable to Nutex Health Inc. for 2024 was $52.1 million, a significant improvement from a net loss of $45.8 million in 2023.
• Total revenue increased by 93.8% to $479.9 million in 2024 from $247.6 million in 2023, primarily driven by the hospital division's successful participation in the Independent Dispute Resolution (IDR) process under the No Surprises Act (NSA), contributing $169.7 million to the increase.
• Adjusted EBITDA for 2024 was $124.1 million, a substantial increase from $10.8 million in 2023.
• Patient visits in the hospital division rose by 16.9% in 2024 compared to 2023, with mature hospitals experiencing 6.5% growth and four new hospital openings contributing to the increase.
• The Population Health Management (PHM) division achieved an operating income of $1.4 million in 2024, a turnaround from a $1.6 million operating loss in 2023, partly due to the divestiture of underperforming entities.
• An additional material weakness in internal control over financial reporting was identified as of December 31, 2024, related to timely and accurate accounting for complex and non-routine matters.
• The company's cash and equivalents increased to $40.6 million at December 31, 2024, from $22.0 million at December 31, 2023, with operating cash flows at $23.2 million for 2024.
• The Pre-Paid Advance Agreement with Yorkville was terminated and fully paid off in February 2024.
• The conversion price of Unsecured Convertible Term Notes and exercise price of related Warrants were amended to $30.00 per share on March 26, 2024.

Sentiment

Score: 7

Explanation: The company demonstrated a strong financial turnaround with significant revenue and profit growth, and improved Adjusted EBITDA. However, this is tempered by the necessity of a financial restatement, the identification of an additional material weakness in internal controls, and ongoing legal proceedings, which introduce uncertainty and risk.

Positives

• Net income attributable to Nutex Health Inc. reached $52.1 million in 2024, a significant turnaround from a $45.8 million net loss in 2023.
• Total revenue increased by 93.8% to $479.9 million in 2024, primarily driven by the hospital division's strong performance.
• Hospital division revenue grew by 106% to $449.1 million in 2024, largely due to successful participation in the Independent Dispute Resolution (IDR) process under the No Surprises Act (NSA), which contributed $169.7 million.
• Adjusted EBITDA saw a substantial increase to $124.1 million in 2024 from $10.8 million in 2023, indicating improved operational profitability.
• Patient visits in the hospital division increased by 16.9% year-over-year, with mature hospitals showing 6.5% growth and contributions from four new hospital openings in 2024.
• The Population Health Management (PHM) division returned to operating income of $1.4 million in 2024, a positive shift from a $1.6 million operating loss in 2023, partly due to strategic divestitures.
• The company achieved an arbitration success rate in excess of 80% during the fourth quarter of 2024 for claims submitted under the IDR process.
• Cash and cash equivalents increased to $40.6 million at year-end 2024, supported by $23.2 million in cash from operating activities.
• The company reversed $6.5 million of its deferred tax asset valuation allowance in 2024, indicating management's increased confidence in future taxable income realization.

Negatives

• The company restated its previously issued consolidated financial statements for 2024 due to misclassifications of non-cash stock-based compensation obligations and related-party accounts payable.
• An additional material weakness in internal control over financial reporting was identified as of December 31, 2024, specifically related to timely and accurate accounting for complex and non-routine matters.
• The company faces ongoing legal challenges, including a securities class action and two derivative actions, alleging violations of securities laws and breaches of fiduciary duties.
• General and administrative expenses increased by $8.6 million in 2024, attributed to higher accrued bonus expense, professional services, and insurance costs.
• Interest expense increased to $19.9 million in 2024, primarily due to new leases for four new facilities.
• The company received a NASDAQ non-compliance notice on August 20, 2025, for the delayed filing of its Form 10-Q for the period ended June 30, 2025.

Risks

• Sales of a substantial amount of common stock by stockholders, or the perception of such sales, could cause the stock price to fall.
• Ineffective internal control over financial reporting could lead to inaccurate financial reports, untimely filings, and a decline in investor confidence and stock price.
• The company may be required to take write-downs or write-offs, restructuring, and impairment or other charges that could significantly negatively affect financial condition, results of operations, and stock price.
• The laws and regulations applicable to public companies are complex and may require increasing management time and increase staffing and compliance costs.
• The new and rapidly evolving business and market make it difficult to evaluate future prospects, risks, and challenges.
• The current business plans require significant capital, and inability to obtain sufficient funding or access to capital could materially adversely affect prospects, financial condition, and results of operations.
• The company may decide to close underperforming hospitals, which could result in a temporary decrease in overall revenues.
• Difficulties in managing growth and expanding operations could strain human and capital resources and lead to deficiencies in controls.
• Recovery of out-of-network claims under the arbitration process is subject to change, and the arbitration success rate could decline significantly.
• Reimbursement methodology and timing for medical services are subject to change, and reimbursement amounts for emergency services could decline.
• Estimates and assumptions used in financial statements, particularly for variable consideration and claims subject to arbitration, may prove inaccurate.
• Public health emergencies could negatively affect operations, business, and financial condition, and the ability to generate revenue.
• Reliance on the management team and key employees means inability to retain qualified personnel could harm the business.
• Growth depends on identifying and developing successful new geographies, physician partners, and patients; failure to execute could have a material adverse effect.
• Conflicts of interest may arise due to the CEO's co-ownership in real estate entities that lease to hospital facilities.
• Inaccurate estimates of target geographies' size, revenue, or medical expenses, or costs exceeding revenue, could impact growth and lead to losses.
• Dependence on reimbursement by third-party payors and individuals could lead to delays and uncertainties in payment timing and process.
• Inability to maintain and expand facilities staffed with qualified physicians would limit future growth.
• Loss of regulatory licenses, permits, and/or accreditation status by physician partners, or ineligibility for reimbursement, could materially adversely affect the business.
• Operating in a competitive industry means inability to compete effectively could harm the business.
• Developments affecting spending by the healthcare industry could adversely affect the business.
• Medical liability claims against the company or physician partners could result in significant expenses and damages not covered by insurance.
• Failure to comply with applicable data interoperability and information blocking rules could adversely affect consolidated results of operations.
• Material information technology system failures, security breaches, or other cybersecurity deficiencies could harm the business.
• Future litigation could be costly and time-consuming to defend.
• Changes in U.S. tax laws and adoption of tax reform policies could adversely affect operating results and financial condition.
• Quarterly results may fluctuate significantly, impacting the value of common stock.
• Obligations under term loans and related guarantees could restrict operations and lead to foreclosure on assets in case of default.
• Arrangements with Variable Interest Entities (VIEs) are not as secure as direct ownership, and failure of equity holders to perform could have an adverse effect.
• Changes in accounting principles or interpretation affecting VIE consolidation could impact reported total revenues.
• Delays in enrolling new physicians and providers in governmental healthcare programs could delay reimbursement.
• Difficulty collecting payments from third-party payors in a timely manner could adversely impact net revenue.
• Decreases in payor rates could adversely affect the company.
• Federal and state laws may limit the ability to collect monies owed by patients.
• Reserves for potential medical claim losses are subject to inherent uncertainties, and deficiencies could reduce assets or net income.
• Lack of a Knox-Keene license could lead to sanctions if the DMHC determines the company is inappropriately taking risk for institutional and professional services in California.
• Affiliated physician groups' inability to satisfy California financial solvency regulations could limit or terminate their ability to do business in California.
• Primary care physicians affiliating with multiple IPAs, including competitors, could lead to lawsuits alleging interference with exclusivity arrangements.
• Inadvertent employment or contracting with an excluded person could lead to government sanctions.
• Substantial costs in protecting or defending intellectual property rights, or failure to protect them, could adversely affect the business.
• Assertions by third parties of infringement or other violations of their intellectual property rights could result in significant costs.
• Inaccurate or incomplete information provided to clients could harm business reputation.
• Proprietary applications may not operate properly, damaging reputation or diverting resources.
• Anti-takeover provisions under Delaware law could make an acquisition more difficult.
• No current plans to pay cash dividends means no return on investment unless stock is sold for a price exceeding purchase price.
• Market price and trading volume of common stock may be volatile and could decline significantly.
• Lack of research or inaccurate/unfavorable research by securities or industry analysts could cause stock price and trading volume to decline.
• Operating as a public company incurs significantly increased costs and requires substantial management time.
• Failure to develop and maintain proper and effective internal control over financial reporting could adversely affect investor confidence.

Future Outlook

The company plans to continue its growth strategy by expanding clinical services at existing facilities, opening three new hospital facilities in 2025, and launching one to three additional IPAs per year, particularly in areas around existing micro-hospitals, with Phoenix, Arizona, being a target market for 2025. The company also anticipates continued legislative and rulemaking efforts related to the No Surprises Act throughout 2025, which could be influenced by a new administration. A share repurchase program of up to $25 million has been authorized to increase shareholder value and offset dilution.

Management Comments

• Management has re-evaluated and determined that there is an additional material weakness in the design and operating effectiveness of internal control over financial reporting as of December 31, 2024, related to timely and accurately analyzing and accounting for complex and non-routine accounting matters.
• Management is undertaking additional efforts to remediate the identified material weaknesses and strengthen the overall control environment, including engaging an accounting firm and training relevant personnel.
• The company's methodology for revenue recognition now incorporates historical arbitration outcomes, payor behavior, and expected resolution timing in determining the expected transaction price for applicable claims, reflecting an improvement in the ability to estimate revenue.
• The divestiture of Procare and Clinigence Health Inc. entities was a strategic move that contributed to improved gross margins from 2024 onward, reinforcing the organization's long-term profitability.

Industry Context

The U.S. healthcare industry is experiencing significant changes, including a growing focus on lower-cost care solutions, a shift from inpatient to outpatient settings, and ongoing consolidation among providers and insurers. National healthcare expenditures are projected to reach nearly $7.7 trillion by 2032, with hospital services remaining the largest category. Regulatory uncertainty, particularly concerning the No Surprises Act (NSA) and its Independent Dispute Resolution (IDR) process, continues to impact reimbursement for out-of-network providers. The company's strategy of developing micro-hospitals and IPAs aligns with the demand for immediate, convenient, and affordable primary and emergency care, especially in underserved markets and for the growing aged population.

Corporate Governance

Legal Proceedings

• A putative securities class action complaint was filed on August 22, 2025, in the U.S. District Court for the Southern District of Texas, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. The company disputes the allegations and intends to vigorously defend the lawsuit.
• Two purported stockholder derivative actions were filed on September 8, 2025, and September 11, 2025, in the U.S. District Court for the Southern District of Texas, alleging violations of Section 14(a) of the Exchange Act, breaches of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets. The company has stipulated to consolidation and intends to defend the matters.

Related Party Transactions

• The company has contractual relationships with Physician LLCs, which employ doctors at its hospitals and are consolidated as Variable Interest Entities (VIEs) due to lack of significant equity at risk and historical support from the company. These entities are owned and, in some instances, controlled by related parties, including the CEO, Dr. Thomas Vo.
• Most hospital division facilities are leased from Real Estate Entities, which are owned by related parties (including the CEO). These leases are typically triple net, with the hospital division responsible for operating costs, repairs, and taxes. Cash payments for these lease obligations totaled $20.0 million in 2024.
• The building housing the company's corporate headquarters is owned by the CEO and leased to the company.
• Real Estate Entities are consolidated as VIEs when they lack sufficient equity at risk and the company's hospital entities guarantee or co-borrow their mortgage loans. Two Real Estate Entities remained consolidated as of December 31, 2024.
• Accounts receivable from noncontrolling interest owners of consolidated hospital facilities totaled $4.3 million at December 31, 2024.
• Advances from Micro Hospital Holding LLC, an affiliate controlled by the CEO, to one hospital facility (SE Texas ER) totaled $3.5 million at December 31, 2024, and were reclassified to equity as intended contribution amounts.
• The company provides managerial services to emergency centers owned and controlled by related parties, including an entity controlled by the CEO, generating zero managerial fees in 2024 (compared to $0.5 million in 2023 and $1.2 million in 2022).

Stakeholder Impact

• Shareholders: Experienced significant dilution from past stock splits, but may benefit from the authorized $25 million share repurchase program. The financial restatement and identified material weaknesses could impact investor confidence and stock price. Ongoing legal proceedings introduce uncertainty and potential financial liabilities.
• Employees: The company employs 800 full-time employees and contracts 255 doctors. The 2023 Equity Incentive Plan and Employee Stock Purchase Plan aim to attract and retain talent. Increased payroll expenses in 2024 reflect growth and bonus accruals.
• Patients: The company's mission to provide concierge-level healthcare and its focus on patient-centric care models aim to improve patient experiences and clinical outcomes. The No Surprises Act and IDR process directly impact patient billing and out-of-network costs.
• Physician Partners: The company's strategy relies on strong relationships with physician partners who are co-investors in micro-hospitals or IPAs. The financial participation and alignment of interests are critical to success.
• Creditors: The company's debt arrangements and lease guarantees, particularly for Real Estate Entities, expose it to financial covenants. Compliance with these covenants is crucial for maintaining financial stability.

Next Steps

• Open three new hospital facilities in 2025, which are currently under construction or in advanced planning stages.
• Launch one to three additional IPAs per year, primarily in geographic areas around existing micro-hospitals, including operationalizing an IPA in Phoenix, Arizona, in 2025.
• Continue remediation efforts to address identified material weaknesses in internal control over financial reporting, including assistance from an accounting firm and ongoing personnel training.
• Vigorously defend against the securities class action and derivative lawsuits filed against the company and its management.
• Execute the authorized stock repurchase program of up to $25 million over the next six months to enhance shareholder value and mitigate dilution.
• Monitor and respond to ongoing legislative and rulemaking efforts related to the No Surprises Act, which may be influenced by a new administration.

Key Dates

Recommendation

Nutex Health Inc. has demonstrated a remarkable financial turnaround in 2024, achieving significant revenue growth and returning to profitability, with a substantial increase in Adjusted EBITDA. The company's strategy of expanding micro-hospitals and IPAs appears to be gaining traction, and its success in the IDR arbitration process is a positive indicator for revenue collection. However, the restatement of prior financial statements, the identification of an additional material weakness in internal controls, and ongoing securities class action and derivative lawsuits introduce considerable uncertainty and risk. While the authorized share repurchase program could provide some support to the stock price, these governance and legal issues warrant caution. A seasoned investor would likely 'hold' to observe the effectiveness of remediation efforts for internal controls and the outcomes of the legal proceedings before making a more definitive investment decision, balancing the strong operational performance against the significant inherent risks.

Keywords

Healthcare, Micro-hospitals, Population Health Management, IPA, SEC Filing, 10-K/A, Financial Restatement, Internal Controls, No Surprises Act, IDR, NUTX, Revenue Growth, Net Income, Adjusted EBITDA, Stock-based Compensation, Legal Proceedings, Share Repurchase